RA Capital Nexus Fund II, L.P.
SEC CIK 1825376 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| HOWL | Werewolf Therapeutics, Inc. | Dir, 10% | 6.02M | $487.2K | — | 1 | 2025-05-12 | 2025-05-12 |
| LENZ | LENZ Therapeutics, Inc. | Dir, 10% | 3.32M | $15.00M | — | 2 | 2024-03-21 | 2024-03-21 |
| ANTX | AN2 Therapeutics, Inc. | 10% | 5.14M | $16.83M | — | 3 | 2022-06-13 | 2023-08-18 |
| JANX | Janux Therapeutics, Inc. | Dir | 8.12M | $6.17M | — | 1 | 2023-07-19 | 2023-07-19 |
| CTKB | Cytek Biosciences, Inc. | Dir | 11.05M | $5.56M | — | 1 | 2022-02-23 | 2022-02-23 |
| CLYM | Climb Bio, Inc. | Dir, 10% | 483.7K | $40.00M | — | 2 | 2021-08-12 | 2021-08-12 |
Most active insiders at HOWL, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | EVNIN LUKE | Dir | — | $3.26M |
| 2 | MPM BioVentures 2014 LLC | 10% | — | $1.09M |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 10% | — | $963.9K |
| 4 | UBS Oncology Impact Fund L.P. | 10% | — | $824.5K |
| 5 | MPM Asset Management Investors BV2014 LLC | 10% | — | $528.5K |
| 6 | MPM Oncology Innovations Fund GP LLC | 10% | — | $528.1K |
| 7 | MPM BioImpact LLC | Former 10% Owner | — | $479.1K |
| 8 | MPM ONCOLOGY INNOVATIONS FUND LP | 10% | — | $391.6K |
| 9 | MPM BioVentures 2014, L.P. | 10% | — | $241.3K |
| 10 | MPM BioVentures 2014 (B), L.P. | Former 10% Owner | — | $183.3K |
RA Capital Nexus Fund II, L.P. made no open-market trades at HOWL in the last 12 months.
Transactions 10
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2025-05-14 | 2025-05-12+ | HOWL | Werewolf Therapeutics, Inc. | RA Capital Nexus Fund II, L.P. | Dir, 10% | P - Purchase | $0.9082 | +536.4K | 6.02M | +10% | +$487.2K |
| DMI | 2024-03-25 | 2024-03-21 | LENZ | LENZ Therapeutics, Inc. | RA Capital Nexus Fund II, L.P. | Dir, 10% | P - Purchase | $15.03 | +998.0K | 3.32M | +43% | +$15.00M |
| DMI | 2024-03-25 | 2024-03-21 | LENZ | LENZ Therapeutics, Inc. | RA Capital Nexus Fund II, L.P. | Dir, 10% | A - Grant | — | +3.25M | 164.7K | New | — |
| I | 2023-08-22 | 2023-08-18 | ANTX | AN2 Therapeutics, Inc. | RA Capital Nexus Fund II, L.P. | 10% | P - Purchase | $9.00 | +1.78M | 5.14M | +53% | +$16.00M |
| DI | 2023-07-21 | 2023-07-19 | JANX | Janux Therapeutics, Inc. | RA Capital Nexus Fund II, L.P. | Dir | P - Purchase | $12.46 | +495.0K | 8.12M | +6% | +$6.17M |
| MI | 2022-07-28 | 2022-07-26+ | ANTX | AN2 Therapeutics, Inc. | RA Capital Nexus Fund II, L.P. | 10% | P - Purchase | $7.78 | +23.2K | 3.76M | +0.6% | +$180.7K |
| MI | 2022-06-15 | 2022-06-13+ | ANTX | AN2 Therapeutics, Inc. | RA Capital Nexus Fund II, L.P. | 10% | P - Purchase | $7.95 | +81.4K | 3.69M | +2% | +$647.5K |
| MI | 2022-02-25 | 2022-02-23+ | CTKB | Cytek Biosciences, Inc. | RA Capital Nexus Fund II, L.P. | Dir | P - Purchase | $13.22 | +420.4K | 11.05M | +4% | +$5.56M |
| DMI | 2021-08-16 | 2021-08-12 | CLYM | Climb Bio, Inc. | RA Capital Nexus Fund II, L.P. | Dir, 10% | P - Purchase | $12.50 | +3.20M | 483.7K | New | +$40.00M |
| DMI | 2021-08-16 | 2021-08-12 | CLYM | Climb Bio, Inc. | RA Capital Nexus Fund II, L.P. | Dir, 10% | C - Cnv Deriv | — | +6.87M | 288.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations